PR99816

LISBON, Portugal, March 22, 2023 /PRNewswire=KYODO JBN/--

This partnership will create an opportunity for the pharmaceutical industry to

develop and manufacture clinical materials and secure industrial scale

production under cGMP with Hovione, using Laxxon Medical's 3D screen printing

technology.

Hovione and Laxxon Medical announced a strategic collaboration to advance the

use of 3D screen printing technologies for the pharmaceutical industry. This

partnership combines Laxxon´s expertise in 3D screen printing, based on their

SPID®-Technology, with Hovione's product & process development, engineering and

manufacturing expertise in pharmaceutical applications. Under the terms of the

agreement, Hovione will establish the Laxxon Medical 3D screen printing

technology at Hovione's cGMP production sites first in Portugal and later in

the USA.

characteristics that cannot be achieved with conventional dosage forms, the

ability to create tablets of any shape and size, the option to easily adjust

the number of active substances and individual components in the composition of

the tablet and even to set the dosage individually for each patient for

personalized medicines.

"Laxxon is thrilled to establish a long-term partnership with Hovione." said

Klaus Kuehne, COO of Laxxon Medical. "This partnership will serve as a great

accelerator in establishing 3D screen printing within the pharmaceutical

industry thus accelerating our ability to serve our customers." "Hovione has a

global reputation for their pharmaceutical innovation services, expertise and

market access. This agreement marks a significant milestone for Laxxon in terms

of our own market strategy and development efforts." said Helmut Kerschbaumer,

Laxxon's CEO. "We are looking forward to collaborating with Hovione to promote

innovation through 3D screen printing."

"We find the Laxxon Medical 3D printing technology to be very innovative and

enabling. It not only allows for the customization and production of drug

products with complex shapes and structures as well as unique API release

characteristics but it also has the potential to reduce the time and cost of

drug development" says Dr. Jean-Luc Herbeaux, Hovione´s CEO. He adds "Hovione

has a track record of turning emerging pharmaceutical production technologies

into reliable and scalable offerings at both developmental and commercial

scales. We are excited at the prospect of supporting Laxxon in industrializing

its 3D printing technology and make it accessible to a greater number of

pharmaceutical and medical device companies."

With this partnership the platform will be available from early development

phases to routine commercial manufacturing.

About Hovione

Hovione is an international company with over 60 years of experience in

pharmaceutical development and manufacturing operations. As a Contract

Development and Manufacturing Organization

(CDMO)(https://www.hovione.com/products-and-services/contract-manufacturing-services) Hovione has a fully integrated offering of services for drug substance,

drug product intermediate and drug product. The company has four FDA inspected

sites in the USA, Portugal, Ireland and China and development laboratories in

Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers

services for the development and compliant

manufacture(https://www.hovione.com/products-and-services/contract-manufacturing-services/particle-engineering) of innovative drugs, including highly potent

compounds, and customized product solutions across the entire drug life cycle.

In the inhalation area, Hovione offers a complete range of services, from API,

formulation development and devices. Hovione's culture is based on innovation,

quality and delivery. Hovione was the first Chemical/ Pharmaceutical Company to

become a Certified B Corp, is a member of Rx-360, EFCG and participates

actively in industry quality improvement initiatives to lead new global

industry standards.

About Laxxon Medical

Laxxon Medical is a pharma-technology company pioneering patented cutting-edge

3D screen printing development and manufacturing solutions for the

pharmaceutical industry. Laxxon's SPID®-Technology (Screen Printing

Innovational Drug Technology) facilitates different pharmaceutical forms of

application such as oral, transdermal, and implantable dosage forms through

geometric shaping and heterogeneous distribution of active ingredients,

enabling different release profiles such as sequential release.

SPID®-Technology is capable of printing small batches for R&D, up to

commercial-scale production without the need to change the manufacturing

process.

SPID®-Technology (3D Screen Printing)

SPID®-Technology (Screen Printed Innovative Drug Technology) is an additive

manufacturing process which enables the development and production of complex

formulations and geometrical structures of oral dosage forms to optimize the

release profiles of common pharmaceuticals in addition to new drug developments.

For more information, please visit www.hovione.com or contact:

Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel.: +351 21 982

9000

Photo: https://mma.prnewswire.com/media/2038240/Hovione_Laxxon_Partnership.jpg

Source: Hovione